Multiple Sclerosis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797402
  • Drug Pipelines
  • 339 pages
  • Datamonitor Healthcare
1 of 3
Competition is mounting in the lucrative multiple sclerosis market, as new entrants and late-stage pipeline candidates look to capture market share from established players.

This report addresses the following questions:

- How have oral disease-modifying therapies changed prescribing trends in multiple sclerosis - and how will they impact overall market sales?
- What are the current leaders of the market-and how will these change by 2023?
- What therapies are under development for progressive multiple sclerosis subtypes?
- Which are the current treatment practices in multiple sclerosis, by disease subtype?
- Which treatment challenges are physicians faced with?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: MULTIPLE SCLEROSIS

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Aubagio (teriflunomide) ,
- Avonex (interferon beta-1a)
- Betaseron/Betaferon (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Nerventra (laquinimod)
- ocrelizumab
- ozanimod
- Plegridy (peginterferon beta-1a)
- ponesimod
- Rebif (interferon beta-1a)
- siponimod
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Zinbryta (daclizumab)
- Primary Research Methodology

TREATMENT: MULTIPLE SCLEROSIS

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Multiple Sclerosis

EPIDEMIOLOGY: MULTIPLE SCLEROSIS

- Executive Summary
- Disease Background
- Global Variations
- Risk Factors
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: MULTIPLE SCLEROSIS

- Executive Summary
- Product Overview
- Appendix
- Product profile: Ampyra
- Product profile: Aubagio
- Product profile: Avonex
- Product profile: Betaseron
- Product profile: Copaxone
- Product profile: Extavia
- Product profile:Gilenya
- Product profile: Lemtrada
- Product profile: Plegridy
- Product profile: Rebif
- Product profile: Tecfidera
- Product profile: Tysabri

PIPELINE: MULTIPLE SCLEROSIS

- Executive Summary
- Clinical Pipeline Overview
- Appendix
- Product profile (late stage): Nerventra
- Product profile (late stage): Zinbryta
- Product profile (late stage): ocrelizumab
- Product profile (late stage): ozanimod
- Product profile (late stage): ponesimod
- Product profile (late stage): siponimod
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll